Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 4Solid Tumors 4Mesothelioma, Malignant 2Mesothelioma 2Advanced Solid Tumors 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumor, Pleural 1Solid Tumor 1Sarcoma 1Salivary Gland Neoplasms 1Relapsed Pediatric Solid Tumor 1Refractory Solid Tumors 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Esthesioneuroblastoma, Olfactory 1Esophageal Neoplasms 1Ependymoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

pazopanib 2Ifosfamide 2Etoposide 2Carboplatin 2vandetanib 1ruxolitinib 1fludarabine 1Vemurafenib 1Trastuzumab 1Sorafenib 1Imatinib Mesylate 1Everolimus 1Erlotinib Hydrochloride 1Dasatinib 1Cytarabine 1Crizotinib 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Relapsed Pediatric Solid Tumor × Erlotinib Hydrochloride × Other solid neoplasm × Clear all
NCT02638428 2020-03-19

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Samsung Medical Center

Phase 2 Unknown
90 enrolled
Other solid neoplasm

Relapsed Pediatric Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡